Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Open Label Dose-Escalation Study to Evaluate the Safety and Immunogenicity of H56:IC31 (AERAS-456) in HIV-negative Adults With and Without Latent Tuberculosis Infection

NCT01967134 is registered in ClinicalTrials.gov with Aeras as lead sponsor.

NCT NCT01967134
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01967134 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Open Label Dose-Escalation Study to Evaluate the Safety and Immunogenicity of H56:IC31 (AERAS-456) in HIV-negative Adults With and Without Latent Tuberculosis Infection
Lead sponsor
Aeras
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2011
Completion date
June 30, 2013
Enrollment
25 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

latent tuberculosis, latent tuberculosis bacteriology and histology unknown